
How to Respond to a USFDA Complete Response Letter (CRL)
USFDA Complete Response Letter (CRL) is not a rejection—it’s a formal notification from the U.S. Food and Drug Administration (USFDA) indicating that…
Regulatory affairs reference · from India
Approval pathways, dossier formats and timelines for USFDA, CDSCO, EMA, MHRA, the GCC and emerging markets, written by regulatory professionals.
Approval pathways, dossier formats and timelines for each regulator.
Step-by-step explainers, reviewed against current agency guidance.

USFDA Complete Response Letter (CRL) is not a rejection—it’s a formal notification from the U.S. Food and Drug Administration (USFDA) indicating that…

USFDA eCTD Submission Process: In today’s digital era, regulatory authorities worldwide are embracing electronic formats for drug submissions. For the U.S. Food…

Before initiating clinical trials for a new drug in the United States, sponsors often engage with the U.S. Food and Drug Administration…

ANDA vs NDA: When it comes to launching a pharmaceutical product in the United States, choosing the correct regulatory submission pathway is…

The pharmaceutical market across Russia and CIS (Commonwealth of Independent States) is one of the most dynamic and complex due to its…

Africa Drug Approval Process: Africa represents a rapidly growing pharmaceutical market, projected to surpass $70 billion USD by 2030. The Africa Drug…
Current openings in regulatory affairs, QA and pharmacovigilance.
What RA hiring managers ask, with model answers.
RAC, PG diplomas and short courses worth the time.
From RA executive to head of regulatory: skills at each step.
Dossier preparation, gap analysis and query responses for USFDA, EMA, CDSCO and emerging markets.